Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Asghar Husain

Sports Medicine Rancho Cucamonga, CA Medical Doctor

NPI 1356438741 CMS profile 106305

8805 Haven Ave, Suite 200, Rancho Cucamonga, CA 91730

Open in the dashboard

General payments

$158,982

287 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Asghar Husain of Rancho Cucamonga, CA is reported in the CMS Open Payments database as having received $158,982 across 287 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $56,596 37
2024 General $31,164 56
2023 General $20,519 68
2022 General $11,846 23
2021 General $1,040 13
2020 General $1,472 13
2019 General $36,345 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Asghar Husain
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Asghar Husain were reported at $56,596. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Asghar Husain Sports Medicine median Middle half National median
2019 $36,345 $1,176 $199–$4,249 $163
2020 $1,472 $708 $96–$2,890 $114
2021 $1,040 $1,213 $152–$3,994 $132
2022 $11,846 $1,230 $159–$3,998 $149
2023 $20,519 $584 $146–$2,836 $160
2024 $31,164 $628 $163–$3,168 $164
2025 $56,596 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $152,222 268 payments
  2. SportsTek Medical, Inc $3,140 2 payments
  3. Surgical Theater. Inc. $991 2 payments
  4. Empire Medical, Inc $858 2 payments
  5. Medical Device Business Services, Inc. $813 6 payments
  6. Stryker Corporation $566 4 payments
  7. Smith+Nephew, Inc. $273 1 payment
  8. DePuy Synthes Sales Inc. $106 1 payment
  9. Ethicon US, LLC $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $127,833 26 payments
  2. Travel and Lodging $20,720 75 payments
  3. Food and Beverage $7,413 185 payments
  4. Education $3,016 1 payment
Products named General payments · program years 2019–2025
  1. SHOULDER SUTURE CERCLAGE CERCLAGE $2,125 1 payment
  2. Bristow Latarjet $813 6 payments
  3. ALPHAVENT $373 2 payments
  4. Regeneten $273 1 payment
  5. SALVATION $175 1 payment
  6. SHOULDER IMPLANTS SPEEDBRIDGE COMPOSITE ANCHORS $120 1 payment
  7. NA $106 1 payment
  8. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $19 1 payment
  9. Echelon; Endopath $13 1 payment
  10. SURGICEL NU-KNIT $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

51

Median for Orthopedic Surgery: 203

Drug cost

$431

Median for Orthopedic Surgery: $1,433

Branded share of claims

56.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 16 $181
Gabapentin Generic 22 $148
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $102

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$77,031

Of which drugs: $3,043

Medicare patients

238

Average age 72

Services billed

937

157 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Diabetes 39%
Chronic kidney disease 26%
Ischemic heart disease 23%
Depression 18%
Osteoporosis 17%
Heart failure 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 32 80 $420
Injection, ropivacaine hydrochloride, 1 mg J2795 Office 30 146 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record